Navigation Links
Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
Date:4/1/2009

LOS ANGELES and TAMPA, Fla., April 1 /PRNewswire/ -- Stem Cell Biotherapy ("SCB") announced that it filed a lawsuit today in Los Angeles County Superior Court against the Company's Co-Founder and former President Casey Nabavi of Calabasas, California, for among other things conduct by Nabavi giving rise to patient claims against Nabavi that he had misrepresented himself as a medical doctor, practiced medicine without a license, supervised the injection of stem cells which caused some patients to become ill and personally advised patients how to manage these side effects. Nabavi/Cellulogix have offices/clinics in Los Angeles, Tampa, Montreal, Zona Rio (Mexico) and Istanbul.

The SCB lawsuit also seeks to recover SCB funds in excess of $1.65 million that Navabi paid himself before leaving SCB, to recover assets including intellectual property belonging to SCB which Navabi took and used to start-up the new Cellulogix business, to prevent Nabavi from continuing to compete with SCB in contravention of the parties' non-competition agreement and for SCB to recover ownership, the business and profits of Cellulogix as belonging to SCB not to Navabi as a result of Nabavi's wrongful conduct and activities. A copy of the SCB lawsuit against Nabavi and Cellulogix can be viewed at the Company's web site www.stemcellbiotherapy.com at "Recent News".

SCB is in the business of assisting persons who desire to try stem cell therapy treatment for serious medical problems which have not responded to traditional medical treatments. SCB uses medical clinics and specialized doctors in locations around the world where stem cell therapy is authorized to treat medical conditions such as spinal cord injury, ALS, Parkinsonism, Alzheimer's, multiple sclerosis, autism, cerebral palsy, brain damage, heart disease, COPD, kidney diseases, eye diseases, diabetes, transverse myelitis, etc. SCB also offers age rejuvenation programs for persons seeking to reverse the effects of aging.

The U.S. FDA recently announced that it was approving Geron Corporation to engage in a clinical trial with embryonic stem cells to treat spinal cord injuries; and the Obama Administration recently reversed the Bush Administration's prohibition against federal funding for embryonic stem cell research.

    For Further Information, Contact
    Burton Feinerman, M.D. at SCB
    1-888-620-0411
   http://www.stemcellbiotherapy.com/


'/>"/>
SOURCE Stem Cell Biotherapy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. A potential molecular target for biotherapy esophageal squamous cell carcinomas
2. IntegriChain Enlists Ed Casey and Associates to Drive Counterfeit and Diversion Monitoring Service
3. The National Association for Home Care & Hospice (NAHC) Joins Sens. Susan Collins and Bob Casey and Reps. Jim McGovern and Walter Jones in Urging Access to Home Health Care
4. Casey Family Programs Hires Ken Patterson as Managing Director of Child and Family Services
5. Casey Family Programs Appoints Dr. America Bracho as New Board Member
6. Casey Family Programs Appoints New Board Members
7. Casey Family Programs Names Alabamas Walley Managing Director for Strategic Consulting
8. Columbus Medicare Diabetes Screening Project Cited as Model for State by Lt. Governor Casey Cagle
9. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
10. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
11. Statement by Steve Case, Co-Founder, AOL and Chairman of Accelerate Brain Cancer Cure (www.ABC2.org) on News of Senator Ted Kennedys Brain Cancer Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: